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The pilosebaceous unit (PSU) response to androgen is variable. Certain population of PSU respond to androgen in
a distinctive pattern that results in sexual hair development in some, sebaceous gland development in others.
Furthermore, androgen excess is variably manifest in women as hirsutism, acne vulgaris, seborrhea, or pattern
alopecia. Although sebaceous cells act as intracrine cells, activating pro-hormones to potent androgens that act
within the sebocyte, hair follicle metabolism predominantly inactivates testosterone. Androgen action in the sexual
hair follicle appears to be mediated by the dermal papilla and possibly, by inducing expression of a speciﬁc keratin,
hHa7, in the hair medulla. The data do not clearly support a relationship between idiopathic hirsutism, the hirsutism
that occurs in the absence of androgen excess, and variations in androgen mechanism of action. Androgens are
prominent among the hormones that modulate the biological mechanism regulating the hair cycle. However, the
basis for the variable pattern of PSU response to androgen is unclear, as is the basis for the variable development
of hirsutism in response to androgen excess and the incomplete reversal of hirsutism by anti-androgen treatment.
Improved treatment of hirsutism awaits improved understanding of the nature of the interaction between
androgens and other determinants of hair follicle biology.
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The pilosebaceous unit (PSU) is known to not only be a
target for androgen and for other hormones, it is additionally
a source of hormones (Deplewski and Rosenfield, 2000;
Alonso and Rosenfield, 2003). This information is here up-
dated with the intent to understand how hormones may
interact with the local PSU factors that regulate hair
morphogenesis and cycling to determine the variable re-
sponse of the PSU to androgen.
The Clinical Enigma
Particular populations of prepubertal vellus follicles in hu-
mans undergo two distinctly different patterns of develop-
ment in response to the normal increase in androgen levels
at puberty: one population develops into sexual hair folli-
cles, whereas another develops into sebaceous glands.
Sexual hair development occurs in a distinctive pattern that
is related to the plasma concentration of androgens. Pubic
and axillary hair develop at plasma androgen levels in the
normal adult female range (testosterone about 20–70 ng per
dL), more sexual hair appears as testosterone levels rise
above the normal adult female range, and full beard and
mustache growth typically occur in response to testoster-
one levels in the normal adult male range (about 310–1100
ng per dL). This suggests that beard PSUs are about one-
tenth as sensitive as axillary hairs to induction of terminal
hair growth by androgens. This contrasts with sebum for-
mation normally being about three-quarters as great at fe-
male levels as at male levels of androgen. Noteworthy is
that some degree of variability in the PSUs response to
androgen is apparent at normal androgen levels. Some
women develop excessive sexual hair in a male pattern (hi-
rsutism) at normal female androgen levels; this ‘‘idiopathic
hirsutism’’ accounts for about half of mild hirsutism. Acne
vulgaris or seborrhea may also occur at normal androgen
levels, indicating a similarly variable response of the seba-
ceous follicle type of PSU to androgen.
Another manifestation of the variability in PSU response
to androgen is pattern alopecia. In this situation, the more
midline scalp hairs anterior to the vertex that have grown
independently of androgens from birth gradually begin to
regress so as to become vellus follicles in genetically sus-
ceptible individuals; the inheritance pattern is polygenic
(Nyholt et al, 2003; Price, 2003). Interestingly, scalp hair
growth is slower at the crown and that of boys is faster than
that of girls in the neonatal period (Solomon and Esterly,
1970). Pattern hair loss (‘‘androgenetic alopecia’’) is most
prominent in men and typically begins in a fronto-temporal
pattern. Adult male plasma androgen levels are a prereq-
uisite; it begins after puberty and increases with age. Fe-
male pattern hair loss ordinarily begins in a fronto-parietal
pattern and is more diffuse. The onset is typically in the third
or fifth decade, and it is androgen independent more often
than not (Olsen, 2001; Vexiau et al, 2002; Price, 2003).
In response to elevated levels of androgen, another as-
pect of the variable PSU response to androgen becomes
Abbreviations: IGF-I, insulin-like growth factor-I; PSU, piloseba-
ceous unit; PTHrP, parathyroid hormone-related peptide
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apparent: hirsutism, acne vulgaris, and pattern alopecia are
variably expressed manifestations of androgen excess. At
modest elevations of androgen (up to about 2-fold) some
women will not develop hirsutism. Some of these cases
have no skin manifestations whatsoever (‘‘cryptic hype-
randrogenemia’’); others have seborrhea, acne, or pattern
alopecia instead (Orfanos et al, 2000). Only as testosterone
levels reach the mid-pubertal male range (over about 5-fold
elevated), will most women have hirsutism; however, the
degree will vary widely, from modest to severe.
These disparities in the response of PSU to androgen
indicate interactions between androgen levels and intrinsic
properties of PSU that can be characterized as differences
in genetic programming or in sensitivity to androgen. What
might be the basis for these variable PSU responses to
androgen? This requires understanding how androgens in-
teract with the PSU and local factors regulating hair biology.
The Endocrinology and
Intracrinology of the PSU
Androgens are primarily secreted by the gonads and adre-
nal cortices. In adult women, these two sets of glands con-
tribute about equally to androgen production; however, half
of androgens in the female are secreted as pro-hormones
(Rosenfield, 1972). The skin is a major site of the metabolic
activation of these hormone precursors (Labrie et al, 2000;
Chen et al, 2002).
Within skin, steroid metabolism occurs in a manner char-
acteristic of the appendage in a manner suggestive that
some of these differences may account for variations in the
responsiveness of these target glands to androgen. The
sebaceous glands and sweat glands account for over 75%
of steroid activation. The sebaceous glands possess the
type 1 3b-hydroxysteroid dehydrogenase, type 5 17b-
hydroxysteroid dehydrogenase, and type 1 5a reductase
activities that, respectively, allow them to convert de-
hydroepiandrosterone (DHEA) sequentially to androstenedi-
one, testosterone, and dihydrotestosterone (DHT). DHT is
the most potent androgen receptor ligand. These enzymes
have recently been localized to the sebocytes themselves
(Thiboutot et al, 2003). Sebocytes express only a trace
amount of cytochrome P450c17, a key enzyme that would
give them the capacity to form DHEA from cholesterol as do
the adrenal glands and gonads. Thus, sebaceous cells act
as intracrine cells, that is, they activate pro-hormones to
potent androgens that act within the cell that forms them
(Labrie et al, 2000).
The enzymatic apparatus of hair epithelium, in contrast,
predominantly functions in the reverse mode, that is, to
inactivate androgen (Glickman and Rosenfield, 1984;
Maudelonde et al, 1986). Nevertheless, it expresses some
5a-reductase and androgen receptor activity, less-so in the
frontal and occipital scalp hair follicles of women than men,
which may be one factor protecting women from andro-
genetic alopecia (Price, 2003).
But the dermal papillae of hair follicles appear to play an
important paracrine role in PSU development by supplying
potent androgens to the closely apposed germinative ma-
trix epithelial cells (Ando et al, 1999). The expression of
mRNA for the type 3 17b-hydroxysteroid dehydrogenase
that most efficiently forms testosterone from androstenedi-
one has been detected. Dermal papillae also express rel-
atively high levels of the 5a-reductase activity that forms
DHT from testosterone. Those of beard possess the most
potent type of 5a-reductase (type 2) activity. Axillary dermal
papillae express type 2 5a-reductase mRNA in greater
amounts than those of beard, although this finding is not
entirely consistent with reported enzyme activity data.
A promising clue to the potential mechanism by which
androgen may specifically stimulate sex hair growth has
recently emerged. The promoter of keratin hHa7, a keratin
specifically expressed in the medulla of sex hairs, contains
an androgen response element that is transactivatable by
androgen (Jave-Suarez et al, 2004).
Is idiopathic hirsutism related to variations in androgen
mechanism of action? Most data does not provide con-
vincing evidence for this possibility. No excessive DHT for-
mation has been detected in plucked sexual hairs. Although
skin of these patients has increased 5a-reductase activity,
this may well be attributable to the sebaceous gland hyper-
plasia that accompanies androgen excess. No abnormality
of androgen receptor binding has been detected in genital
skin fibroblasts, and skewed X inactivation—with shorter
CAG repeats being expressed significantly more—is doubt-
ful as two of three studies have been negative.
Some idiopathic hirsutism patients have sexual hairs that
are larger than normal (Glickman and Rosenfield, 1984).
Sexual hair development, particularly the larger hairs of the
beard, can be reversed by about 50% at most by combi-
nation treatment with anti-androgen and gonadotropin sup-
pression (Giltay and Gooren, 2000; Farquhar et al, 2003; Van
der Spuy and le Roux, 2003).
Dermal papilla cells seem to be the primary target of
androgen in hair. Androgen stimulates the growth of hair
outer root sheet cells only in the presence of co-cultured
dermal papilla cells (Itami et al, 1995). Insulin-like growth
factor-I (IGF-I) appears to mediate this hair epithelial cell
growth in response to androgen. These observations sug-
gest that variations in androgen action depend upon the
interaction of androgens with other biological factors. What
is known about this?
Hormonal Interactions with Hair
Morphogenesis and Cycling
All available evidence suggests that hair follicle morpho-
genesis is hormone independent. Males and females are
born with a similar number of PSU. It is their differentiation
pattern that is determined by androgen, not their number.
IGF-I receptor deletion mutants have small sparse hair fol-
licles, but this appears to be a consequence of the general
blighting of growth of the skin, indeed the body, as a whole.
The only point in PSU morphogenesis at which any hormo-
nal factor has been specifically incriminated is in the tran-
sition from the hair peg stage, the branch point at which the
hair follicle lineage and the sebaceous gland lineage di-
verge. Along with Indian hedgehog (Niemann et al, 2003)
and tumor necrosis factor receptor-associated factor 6, para-
thyroid hormone-related peptide (PTHrP) is a determinant
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of the sebaceous gland lineage. Prenatal over-expression
of PTHrP has a sexually dimorphic, spatially limited effect
on hair growth: ventral hairs are sparse, particularly in
females. The sexual dimorphism appears to have an indirect
basis, however (Abdalkhani et al, 2002). The apparent se-
quence of events is that androgens normally suppress
mammary gland development, so that males have too little
mammary epithelium to express sufficient PTHrP to pro-
mote mammary development at the expense of hair follicle
development. Only females have sufficient mammary gland
development to express enough PTHrP to suppress ventral
hair growth.
It is the hair follicle cycle that is hormone dependent.
Multiple hormonal factors interact with various growth fac-
tors, transcription factors, and transcriptional co-regulators
expressed by the hair follicle, such as fibroblast growth
factor 5, deletion of which underlies the angora mouse mu-
tation by prolonging anagen. Hormonal factors known to
affect the hair cycle are shown in Table I.
Notably, of these, only androgen and the growth hor-
mone/IGF system are known to stimulate hair growth.
Growth hormone potentiates the effect of androgen on
sexual hair growth; about 5-fold more testosterone is re-
quired to induce axillary hair in growth hormone-deficient
than in growth hormone-sufficient hypogonadal boys. IGF-I
is produced by the dermal papilla cells, but not by hair
epithelial cells, and the IGF-I receptor is expressed by hair
matrix epithelium as well as by dermal papilla cells, thus
constituting an autocrine–paracrine system for hair growth.
IGF-I (or high-dose insulin) is necessary for hair follicle
growth in vitro.
Most other hormonal factors promote catagen entry. Al-
though glucocorticoids promote catagen (Paus et al, 1994),
paradoxically glucocorticoid excess causes hypertrichosis.
Most evidence indicates that estrogen promotes catagen
(Conrad and Paus, 2004; Ohnemus et al, 2004). Thus, est-
rogen may be responsible for the arrest of hair growth late in
pregnancy (Solomon and Esterly, 1970), which sets the
stage for telogen effluvium upon the withdrawal of preg-
nancy hormones. On the other hand, the higher expression
of aromatase in the scalp hairs of women than men,
particularly on the occiput, suggests that local estrogen
formation from testosterone may play a role in protecting
them from alopecia (Price, 2003).
The PTHrP/receptor system constitutes a paracrine sys-
tem within the hair follicle. Hair epithelium expresses PTHrP,
whereas the dermal papilla and dermal sheath express its
receptor (Cho et al, 2003; Thomson et al, 2003). Postnatally,
PTHrP or parathyroid hormone, which interacts with the
same receptor, promotes catagen, and PTHrP over-expres-
sion partially corrects the long hair of angora mice. The
PTHrP effect is independent of serum calcium levels and is
being explored as a way of protecting hair follicles from
chemotherapy-induced alopecia (Peters et al, 2001).
An autocrine–paracrine role for prolactin within the hair
follicle is suggested by the fact that prolactin and its recep-
tor have been localized to different portions of the hair follicle
epithelium (Foitzik et al, 2003). Although prolactin adminis-
tration induces premature entry into catagen, clinically pro-
lactin excess is associated with hirsutism, probably because
of stimulation of hyperandrogenism by prolactin excess.
Thyroid hormone appears to regulate the frequency of
the hair cycle: hypothyroidism leads to decreased frequency
of anagen, whereas hyperthyroidism leads to thin hairs.
Triiodothyronine therapy improves hair growth of the hairless
(Hr) mouse, which has congenital total atrichia, although the
thyroid hormone mechanism of action is unlikely to involve
the Hr gene product (Engelhard and Christiano, 2004).
Notably, the vitamin D-retinoid X receptor system is nec-
essary for postnatal cycling of the hair follicle. This occurs
by interaction with the Hr transcription factor (Hsieh et al,
2003). These effects are ligand independent. Consequently,
individuals born with vitamin D receptor deletions suffer
from postnatal alopecia that cannot be corrected by cal-
cium administration.
Summary
The basis for the variable pattern of PSU response to an-
drogen is unclear, as is the basis for the variable develop-
ment of hirsutism in response to androgen excess and the
incomplete reversal of hirsutism by anti-androgen treatment.
Improved treatment of hirsutism awaits improved under-
standing of the nature of the interaction between androgens
and other determinants of hair follicle developmental biology.
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